You are viewing the site in preview mode

Skip to main content

Table 5 Base case results of the health-economic model to determine the ICER of CSII therapy compared to MDI therapy, from the IMSS perspective

From: Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security

Outcomes
Efficacy CSII MDI Absolute difference
Life expectancy (discounted years) 12.593 11.897 0.696
Life expectancy (undiscounted years) 25.036 22.508 2.528
QALYs 7.052 6.438 0.614
Costs MXN (CSII) USD (CSII) MXN (MDI) USD (MDI) MXN (Δ) USD (Δ)
Total costs 1,404,173 76,355 1,110,573 60,390 293,600 15,965
Treatment 693,515 37,712 281,555 15,310 411,960 22,401
Management 14,807 805 14,102 767 705 38
Cardiovascular disease 45,771 2,489 48,047 2,613 2,276 124
Renal care 204,628 11,127 215,608 11,724 10,980 597
Ulcer/amputation/neuropathy 296,320 16,113 323,908 17,613 27,588 1500
Eye care 137,213 7461 135,399 7363 1814 99
Hypoglycemia 10,003 544 90,044 4896 80,041 4352
Incremental cost effectiveness ratioa MXN USD
Incremental cost effectiveness ratio per LYG 434,577 23,631
Incremental cost effectiveness ratio per QALY gained 478,020 25,993
  1. aResults are estimated using all decimal points included in the model, and as such show differences to results calculated using the data presented in the table
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us